Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Lemaitre Vascular Inc. (LMAT:NASDAQ), powered by AI.
Lemaitre Vascular Inc. is currently trading at $93.95. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Lemaitre Vascular Inc. on Alpha Lenz.
Lemaitre Vascular Inc.'s P/E ratio is 36.8.
“Lemaitre Vascular Inc. trades at a P/E of 36.8 (premium valuation) with strong ROE of 15.8%. 3Y revenue CAGR of 15.6% highlights clear growth momentum.”
Ask for details →Lemaitre Vascular Inc. is a prominent medical device company specializing in the development and production of innovative surgical solutions for patients with peripheral vascular disease. As a key player in healthcare, the company's primary objective is to enhance the quality of life and improve outcomes for patients suffering from vascular ailments. Lemaitre Vascular’s comprehensive product portfolio includes a range of grafts, stents, patches, and biologic solutions designed specifically for vascular surgery, endovenous interventions, and diagnostic procedures. The company's products serve a crucial role in the medical industry, particularly within the cardiovascular and peripheral vascular markets. By addressing complex surgical needs and offering specialized vascular solutions, Lemaitre Vascular supports healthcare professionals worldwide in delivering life-saving treatments. Its commitment to research, development, and innovation positions it as a significant contributor to the medical technology sector, ensuring continuous advancement in surgical techniques and patient care.
“Lemaitre Vascular Inc. trades at a P/E of 36.8 (premium valuation) with strong ROE of 15.8%. 3Y revenue CAGR of 15.6% highlights clear growth momentum.”
Ask for details →Lemaitre Vascular Inc. (ticker: LMAT) is a company listed on NASDAQ in the Healthcare sector (Medical Instruments & Supplies). It has approximately 651 employees. Market cap is $2.1B.
The current price is $93.95 with a P/E ratio of 36.84x and P/B of 5.4x.
ROE is 15.80% and operating margin is 27.21%. Annual revenue is $250M.